MAP2K7 and adrenal cortex carcinoma: A further caveat is that it remains unclear if, for example, OnkoKB target level 1 agents such as the MEK inhibitor Selumetinib, which has proved very successful in neurofibromatosis, might also help the 10% of ACC patients bearing NF1 alterations: to date, Selumetinib produced no significant result in NSCLC [73,74], uveal melanoma [75] and other cancers [76], despite NF1 mutations.